SkyQuest Technology Group recently introduced Liquid Biopsy Market study with in-depth overview, describing about the Product/Industry Scope and elaborates market outlook and status (2025-2032). The market Study is segmented by key regions which is accelerating the marketization. The Liquid Biopsy Market has witnessed Excellent growth over the past decade and is expected to maintain its upward trajectory.
Liquid Biopsy Market size was valued at USD 7.6 billion in 2023 and is poised to grow from USD 8.75 billion in 2024 to USD 26.95 billion by 2032, growing at a CAGR of 15.1% during the forecast period (2025-2032).
Growth factors for the liquid biopsy market growth include a growing prevalence of cancer, technological advancements in the field of cancer diagnostics, and a growing preference for minimally invasive cancer diagnostics. Moreover, ongoing research in liquid biopsy assays and tests, aided by the rising adoption and development of multi-cancer early detection tests, presents growth opportunities for the overall market.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/liquid-biopsy-market
One of the most advanced technologies related to genetic alterations and used for the detection of a tumor is liquid biopsy. It has been used in the stratification of the tumor, thereby offering targeted therapy to the cancer. For instance, the FDA approved, in January 2023, the liquid biopsy assay Guardant360 CDx by Guardant Health as a companion diagnostic to diagnose ESR1 mutant breast cancer. Recent inventions, progressions, and expansion in this sector boost liquid biopsy and foster market growth.
Another critical growth opportunity for the liquid biopsy market is provided by Multi Cancer Early Detection (MCED). The MCED market is an emerging sector of interest for the diagnostics industry as it allows the early detection of cancer and, consequently, the early treatment of such patients by saving time and minimizing the risk of such invasive medical surgical procedures. Some disadvantages of single cancer tests include high false-positive rates and optimized sensitivity.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Liquid Biopsy Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Product
Assay Kits, Instruments, Services
Circulating Biomarker
Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA, Extracellular Vesicles, Other Circulating Biomarkers
Technology
Multi-Gene Parallel Analysis Using NGS, Single-Gene Analysis Using PCR
Application
Cancer Applications (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Cancers), Non-Cancer Applications (Non-Invasive Prenatal Testing, Organ Transplantation, Infectious Disease Testing)
Clinical Application
Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring
Sample Type
Blood Samples, Other Sample Types
End User
Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers, Other End Users
Liquid Biopsy Market – Regional Analysis:
– Liquid Biopsy North America Market includes (Canada, Mexico, USA)
– Liquid Biopsy Europe Market includes (Germany, France, Great Britain, Italy, Spain, Russia)
– Liquid Biopsy Asia-Pacific Market includes (China, Japan, India, South Korea, Australia)
– Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa)
– Liquid Biopsy South America Market includes (Brazil, Argentina)
– Liquid Biopsy Oceania Market (Australia & New Zealand)
Top Market Players in Liquid Biopsy Market are:
F. Hoffmann-La Roche Ltd (Switzerland)
Thermo Fisher Scientific Inc. (US)
Illumina, Inc. (US)
Guardant Health, Inc. (US)
Biocept, Inc. (US)
Sysmex Corporation (Japan)
Natera, Inc. (US)
Biocartis Group NV (Belgium)
Bio-Rad Laboratories, Inc. (US)
OncoCyte Corporation (US)
Adaptive Biotechnologies Corporation (US)
Angle PLC (United Kingdom)
Epic Sciences, Inc. (US)
Neogenomics Laboratories (US)
CellMax Life (US)
Menarini-Silicon Biosystems (Italy)
Lunglife AI Inc. (US)
Liquid Biopsy Key Market Trends:
Big Data Analytics in Combination with AI: Liquid biopsy analysis integrates AI and machine learning algorithms in the diagnosis process to make more accurate and detailed classifications of cancers. Machine learning data analysis powered by AI improves the diagnosis of the distinct genetic alterations existing in the tumors and guides oncologists towards more efficient treatment decisions faster than ever before. Besides, aggregated genetic data obtained with big data analytics has resulted in finding novel biomarkers for improving liquid biopsy procedures.
Extension of Liquid Biopsy Outside of Oncology: Although its core application is for cancer diagnostics, liquid biopsy has gained popularity across various therapeutic domains, such as infectious illness diagnosis, organ transplantation monitoring, and prenatal genetic screening. Researchers have been studying it for cardiovascular diseases and neurological conditions such as Parkinson’s and Alzheimer’s. The non-oncology domain entry promises significant growth to the diagnostic companies looking to diversify their offerings.
Also Read –
https://www.openpr.com/news/3948311/microgrid-market-high-impact-drivers-and-revenue
https://www.newstrail.com/synthetic-rubber-market-opportunities-assessment-analysis-trends-and-forecast-2025-2032/
Forward-Looking Insights
The Liquid Biopsy Market is set to experience sustained growth, fueled by technological advancements, broader market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
